ClinicalTrials.gg
CompletedNCT03462069Updated Apr 25, 2022

Comparison of Pharmacodynamic Effects of Sotagliflozin and Empagliflozin in T2DM Patients With Mild to Moderate Hypertension

A Phase 2 interventional study of Sotagliflozin (SAR439954) and Placebo in Diabetes Mellitus, sponsored by Sanofi. Completed at 1 site in Germany. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2022-04-25.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
41
Allocation
Randomized
Ages
18 Years to 74 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Diabetes Mellitus by Sanofi — none open to participants now, none under way, none of them phase 3. Diabetes Mellitus · Sanofi.

Enrollment
22nd of 31
41 · median 188
Started
2018
with 2 others
Phase 2
2 of 33
none open now
Registered
31st of 33
by date

Among the 33 studies in Diabetes Mellitus by Sanofi, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 2 in phase 2, and was the 31st registered.

Diabetes Mellitus

8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

None of the 33 studies in Diabetes Mellitus by Sanofi is open now. The open studies under Diabetes Mellitus, anywhere →

Who these studies take

Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.

This study: 18 Years to 74 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 33 studies in Diabetes Mellitus by Sanofi as a file.
02

Study summary

Primary Objective:

To compare the metabolic and gastrointestinal pharmacodynamic (PD) effects of an 8 weeks treatment with sotagliflozin once daily (QD) to an 8 weeks treatment to empagliflozin QD in mild or moderate hypertensive T2DM patients on a stable treatment regimen with metformin and an angiotensin converting enzyme (ACE) inhibitor or Angiotensin Receptor Blocker (ARB) under standardized diet conditions.

Secondary Objectives:

  • To compare the renal and cardiovascular PD effects of an 8 weeks treatment with sotagliflozin QD to an 8 weeks treatment to empagliflozin QD in mild or moderate hypertensive T2DM patients on a stable treatment regimen with metformin and an ACE inhibitor or ARB.
  • To evaluate the safety and tolerability of an 8 weeks QD treatment with sotagliflozin or empagliflozin in mild to moderate hypertensive T2DM patients on a stable treatment with metformin and an ACE inhibitor or ARB.
  • To evaluate the pharmacokinetic (PK) profile of sotagliflozin in steady state conditions.
Read the detailed description

The total study duration per patient is 70-105 days (for patients without drug washout/switch period), and up to 175 days (for patients with drug washout/switch period), including 2-30 days of screening, 5 days of run-in period, 56 days of treatment period, and a 7-14 days of follow-up period.

03

Conditions studied

  • Diabetes Mellitus

Browse trials for

04

Who can participate

Ages eligible
18 Years to 74 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients with Type 2 Diabetes Mellitus (T2DM) (diagnosed at least 1 year before screening visit), between 18 and 74 years of age, inclusive, with:

    • Hypertension grades 1 or 2 as defined by the European Society of Hypertension (ESH)/European Society of Cardiology (ESC) at screening; systolic blood pressure (SBP) has to be in the range of 140-179 mmHg (after 10 minutes resting in supine position, measurement in triplicate with each measurement to be within this range at screening). If the blood pressure (BP) range is not met at screening, one repeat measurement at another occasion is allowed prior to inclusion into the study.
    • A1c (HbA1c) at screening between 6.5% and 11%.
  • On a stable treatment with metformin, i.e., no change in dose regimen or in dose levels in the last 3 months prior to screening and throughout the study.
  • On a stable treatment with an angiotensin converting enzyme (ACE) inhibitor or an angiotensin receptor blocker, i.e., no change in dose regimen or in dose levels in the last 4 weeks prior to screening and until randomization.
  • On a stable treatment with an ACE inhibitor or an angiotensin receptor blocker after switching from beta-blockers and/or thiazides for eligible patients after screening, i.e., no change in dose regimen and in dose levels in the last 4 weeks prior to run-in phase and until randomization
  • Body weight between 50.0 kg and 130 kg, inclusive, if male, and between 40.0 kg and 110 kg, inclusive, if female, between 18.0 and 38.0 kg/m2, inclusive.
  • Kidney function: Estimated at screening must be 60 mL/min/1.73m2 or higher.

Exclusion criteria

Exclusion criteria:

  • Patients with severe anemia, severe cardiovascular, gastrointestinal, respiratory, neurological, osteomuscular, psychiatric, or active malignant tumor or other major systemic disease or patients with infectious disease, signs of acute illness, or short making implementation of the protocol or interpretation of the study results difficult (as evaluated by detailed medical history and complete physical and laboratory examination).
  • Heart failure (NYHA) Classification III/IV.
  • Any abnormality in echocardiography performed at screening as judged by the investigator based on age, gender and medical history of the individual patient.
  • History of myocardial infarction within the last 12 months prior to screening.
  • Likelihood of requiring treatment during the study period with drugs not permitted by the study protocol (e.g., long-term systemic ) and refusing or unable to take alternative treatment.
  • Type 1 diabetes mellitus.
  • Secondary hypertension of any etiology (eg, renovascular disease, pheochromocytoma, Cushing's syndrome).
  • Clinically significant pulmonary hypertension, in particular World Health Organisation (WHO) Classes IV (Pulmonary hypertension due to chronic thrombotic and/or embolic disease [CTEPH]) and V (miscellaneous).
  • Diabetic retinopathy.
  • History of diabetic ketoacidosis or non-ketotic hyperosmolar coma within 12 weeks prior to the Screening Visit.
  • History of severe hypoglycemia resulting in hospitalization or unconsciousness/seizures within 6 months prior to the Screening visit.
  • History of prior gastric or intestinal surgical procedure including gastric banding within 3 years before the Screening Visit. Any gastrointestinal surgery with removal of part of the bowels or the stomach
  • History of unexplained pancreatitis, chronic pancreatitis, stomach/gastric surgery, inflammatory bowel disease.
  • Known to sotagliflozin, empagliflozin or any of the drug products.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
41 participants (actual)

Study arms

  • Experimental
    Treatment A (Test)

    Sotagliflozin 2 tablets administered once daily with 1 empagliflozin placebo capsule prior to the first meal of the day

    Drug: Sotagliflozin (SAR439954) · Drug: Placebo

  • Active comparator
    Treatment B (Reference)

    Empagliflozin 1 capsule administered once daily with 2 sotagliflozin placebo tablets prior to the first meal of the day

    Drug: Placebo · Drug: Empagliflozin

Interventions

  • Pharmaceutical form: tablet Route of administration: oral

  • DrugPlacebo

    Pharmaceutical form: tablet Route of administration: oral

  • Pharmaceutical form: capsule Route of administration: oral

    Also known as: Jardiance®

  • DrugPlacebo

    Pharmaceutical form: capsule Route of administration: oral

06

What researchers measure

Primary outcomes

  1. Assessment of pharmacodynamic (PD) parameters in feces

    Change from baseline in fecal sodium excretion

    Time frame: Baseline and on Day 55 and 56 (over 48 hours)

  2. Assessment of pharmacodynamic (PD) parameters in feces

    Change from baseline in fecal short-chain fatty acids (SCFA)

    Time frame: Baseline and on Day 55 and 56 (over 48 hours)

  3. Assessment of pharmacodynamic (PD) parameters in feces

    Change from baseline in fecal pH

    Time frame: Baseline and on Day 55 and 56 (over 48 hours)

  4. Assessment of PD parameters in urine

    Change from baseline in 24-hour urinary glucose excretion

    Time frame: Baseline and on Day 56 (over 24 hours)

  5. Assessment of PD parameters in urine

    Change from baseline in 24-hour sodium excretion

    Time frame: Baseline and on Day 56 (over 24 hours)

  6. Assessment of PD parameters in blood

    14 hour plasma glucose profile after standardized meals

    Time frame: Baseline and on Day 56

  7. Assessment of PD parameters in blood

    14 hour plasma glucagon-like peptide 1 (GLP-1) profile after standardized meals

    Time frame: Baseline and on Day 56

Secondary outcomes

  1. Fasting metabolic laboratory panel

    Change from baseline in fasting plasma glucose

    Time frame: Baseline and on Day 56

  2. Ambulatory Blood Pressure Measurement (ABPM)

    Change from baseline in average 24h systolic arterial pressure

    Time frame: Baseline and on days 54 until Day 56

  3. Cardiovascular parameters

    Change from baseline in plasma aldosterone

    Time frame: Baseline and on Day 56

  4. Pulse wave velocity

    Change from baseline in carotid-femoral pulse wave velocity

    Time frame: Baseline and on Day 55

  5. Continuous Glucose Monitoring (CGM)

    Change from baseline in average diurnal glucose

    Time frame: Baseline, last 3 days of treatment

  6. Echocardiography

    Change from baseline in left ventricular ejection fraction (LVEF)

    Time frame: Baseline and on Day 54

  7. Echocardiography

    Change from baseline in left ventricular end-diastolic diameter

    Time frame: Baseline and on Day 54

  8. Plasma Volume Measurement

    Change from baseline in plasma volume

    Time frame: Baseline and on Day 54

  9. Adverse events

    Number of patients with reported adverse events

    Time frame: Over 15 weeks

  10. Assessment of pharmacokinetic (PK) parameters: Cmax

    Sotagliflozin: maximum plasma concentration observed (Cmax)

    Time frame: 24 hours after last investigational medicinal product (IMP) administration

  11. Assessment of pharmacokinetic (PK) parameters: Ctrough

    Sotagliflozin: plasma concentration observed before administration during repeated dosing (Ctrough)

    Time frame: 24 hours after last IMP administration

  12. Assessment of pharmacokinetic (PK) parameters: AUCtau

    Sotagliflozin: Area under the plasma concentration versus time curve calculated using the trapezoidal method over the dosing interval (AUCtau)

    Time frame: 24 hours after last IMP administration

  13. Assessment of pharmacokinetic (PK) parameters: tmax

    Sotagliflozin: First time to reach Cmax (tmax)

    Time frame: 24 hours after last IMP administration

07

Study locations

1 site
  • Investigational Site Number 2760001
    Berlin, 10117, Germany
08

References and documents

Publications

  • Posch MG, Walther N, Ferrannini E, Powell DR, Banks P, Wason S, Dahmen R. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study. Diabetes Care. 2022 Sep 1;45(9):2118-2126. doi: 10.2337/dc21-2166. PubMed 35817022 ↗

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Apr 2019, 13 months.

Of 65 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 28. This study's 13 months is close to that.

Counting every sponsor, half of 147 studies reached it within 27 months; a quarter within 12 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2018
First posted
Mar 12, 2018
StartActual
Mar 12, 2018
Primary completionActual
Apr 18, 2019
CompletionActual
Apr 18, 2019
Last update
Apr 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03462069
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 12, 2018
Start date
Mar 12, 2018
Primary completion
Apr 18, 2019
Completion
Apr 18, 2019
Last update
Apr 25, 2022

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotagliflozin

Start the discussion